Chinanews.com Beijing, September 17th. On the 16th, Baiyang Pharmaceutical announced that it has signed a strategic cooperation agreement with Ailisi Pharmaceuticals. The two parties will cooperate closely on the construction of various forms of capital cooperation, the listing of patent drugs, and product supply chains. Jointly improve the accessibility of innovative drugs in China.

  According to reports, the strategic cooperation between Baiyang Pharmaceuticals and Ailisi Pharmaceuticals this time will focus on the commercialization of innovative drugs and capital cooperation.

In terms of commercialization cooperation, Baiyang will give full play to the advantages of resources in the industry for many years, and provide Ailisi Pharmaceuticals with overall solutions in terms of patent drug listing, national DTP pharmacy channel services, hospital access and supply chain services, etc., and help Ailisi Sri Lanka's innovative products have achieved terminal market coverage and quickly entered application scenarios.

  In terms of capital cooperation, the two parties will discuss in-depth cooperation in capital areas such as equity and investment, and build various forms of capital cooperation, with a view to maximizing the value of both parties in the pharmaceutical market.

  Fu Gang, Chairman of Baiyang Pharmaceutical Group, said that in the rare historical period of the rise of China's innovative drug industry, Alis Pharmaceuticals, as a rising star in the local innovative drug industry, has strong R&D capabilities and industrialization systems. This is precisely the commercialization of Baiyang. Excellent partner opened by the platform "Highway".

Baiyang, as a professional commercial platform-based enterprise, is cooperating with Iris. It is hoped that both parties will give full play to their strengths and jointly promote the availability of local innovative drug products and provide patients with better medical and health products and services.

  Du Jinhao, Chairman of Iris Pharmaceuticals, stated that Iris has been committed to the research and development of innovative drugs and hopes to build Iris into an innovative modern pharmaceutical enterprise integrating R&D, production and sales in the future.

Now is the key stage of the development and transformation of Iris, and it is very necessary to move forward side by side with excellent partners with industry resources. I believe that after cooperation with Baiyang Pharmaceuticals, it will further realize the complementary advantages and strategic win-win of both parties, and accelerate innovative drugs. Enter the market quickly and bring good news to cancer patients.

  According to reports, in recent years, the country has continuously introduced policies to encourage drug innovation, the policy environment for innovative drugs has been fundamentally improved, and the research and development of innovative drugs has entered a period of rapid development.

At the same time, many companies have begun to deploy new drug R&D and innovation, and companies with continuous R&D and innovation capabilities and continuous launch of innovative drug products on the market have continued to highlight their corporate value.

  According to Baiyang, Baiyang will rely on its omni-channel management, multi-category collaboration, and digital marketing capabilities to fully assist Alis Pharmaceuticals to accelerate its strategic layout in the field of innovative drugs, promote the development of innovative drugs in China, and make valuable New and good drugs benefit more patients.

(Finish)